| Name | Title | Contact Details |
|---|
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.
IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake`s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau.
Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego`s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva`s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.